Kyverna Therapeutics (KYTX) Receivables - Accured (2024 - 2026)

Kyverna Therapeutics (KYTX) posted Receivables - Accured of $1.2 million for Q1 2026, up 100.0% on a QoQ basis from $600000.0 in Q4 2025.

Kyverna Therapeutics (KYTX) Receivables - Accured (2024 - 2026) Analysis & Trends

Kyverna Therapeutics' Receivables - Accured history runs 3 years deep, the most recent figure standing at $1.2 million for Q1 2026.

Quarterly Receivables - Accured changed N/A year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (changed N/A YoY) and the FY2025 annual result came in at $600000.0, changed N/A from the prior year.
Receivables - Accured was $1.2 million for Q1 2026 at Kyverna Therapeutics, up from $600000.0 in the prior quarter.
Across five years, Receivables - Accured topped out at $1.2 million in Q1 2026 and bottomed at $100000.0 in Q2 2024.
A 3-year average of $520000.0 and a median of $400000.0 in 2024 frame the typical range for Receivables - Accured.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables - Accured (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	1.53 Mn
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	-
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	-
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	Kyverna Therapeutics	447.52 Mn	447.52 Mn	-	1.20 Mn

Download Data